|
Society for Prevention Research Annual Conference (SPR)
|
Meeting/ Workshop
|
CDC, ACF
|
NIAAA, NCCIH, NCI, NIDA, OD/DPCPSI/ODP
|
This annual conference is funded by an R13 award and is co-funded by several other NIH Institutes as well as the ACF and the CDC.
|
|
Somatic Cell Genome Editing
|
Research Initiative
|
FDA
|
OD/DPCPSI/OSC, NCATS, NCI, NHGRI, NHLBI, NIAID, NIAMS, NIDDK, NIMH, NINDS, OD/DPCPSI/ORIP
|
The Somatic Cell Genome Editing (SCGE) program aims to develop quality tools to perform effective and safe genome editing in human patients. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. A representative from Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) plays an advisory role for the program regarding regulatory issues. The SCGE program is a member of the National Institute of Standards and Technology (NIST) Gene Editing Consortium. The SCGE program also coordinates with the DARPA Safe Genes program when appropriate.
|
|
Standardization of Lab Data to Enhance Outcomes Research and Value Based Care (SHIELD)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NLM
|
This project will expand the collaborative efforts of FDA and other stakeholders involved in the SHIELD initiative to ensure laboratory information interoperability, such that the same type of device is described the same way in electronic health records (EHR) systems. To realize this goal, this project will develop code mapping manuals to consistently map the same LOINC (Logical Observations Identifiers Names and Codes) to the same type of IVD. This is important because without the specific guidance, manufacturers of IVD devices and laboratories often assign different (and frequently incorrect) LOINC codes for the same type of device. This project will also pilot implementation of SHIELD standard digital formats to update infrastructure in active healthcare provider laboratories, which will include the seamless distribution of LOINC and SNOMED-CT (Systematized Nomenclature of Medicine--Clinical Terms) coding to those provider institutions and registries.
|
|
Standardized Machine-Readable Units of Measure
|
Committee, Work group, Advisory group, or Task Force
|
IOS
|
NLM
|
NLM works with the National Institute of Standards and Technology (NIST) to promote the use of UCUM as a replacement for ISO-8000. NLM develops, disseminates, and facilitates adoption of universal standards (e.g., Unified Code for Units of Measure (UCUM) so that clinical measures reported in different units by different institutions can be converted to a single unit of measure. We have also developed a web-based open source tool to enable the conversion of units of measure to standard machine-readable format using UCUM.
|
|
Standards for Genetic Testing Report
|
Research Initiative
|
AHRQ, CDC, IOS
|
NLM, NHGRI
|
NLM collaborates with NIGMS, AHRQ, CDC, and the Immediate Office of the Secretary of HHS to develop a standard reporting format for genetic variations using Logical Observation Identifiers Names and Codes (LOINC) and HL7, for electronic medical records health information exchange, and activities of the Office of the Secretary.
|
|
State Cancer Profiles
|
Resource Development
|
CDC
|
NCI
|
State Cancer Profiles is an interactive mapping engine produced in collaboration between the National Cancer Institute and Centers for Disease Control and Prevention. It was developed with the idea to provide a geographic profile of cancer burden in the United States and reveal geographic disparities in cancer incidence, mortality, risk factors for cancer, and cancer screening across different population subgroups. The target audiences are health planners, policy makers, and cancer information providers who need quick and easy access to cancer related data and maps to inform and prioritize investments in cancer control.
|
|
State of Illinois - Governor& Challenge
|
Committee, Work group, Advisory group, or Task Force
|
SAMHSA
|
CC
|
Outcome Measurements for Interventions to Decrease Veteran Suicide. This collaboration works to measure various outcomes for interventions to decrease suicide among US Veterans. Following this evaluation, the group will make recommendations based of their assessments.
|
|
Steering Committee Meeting for PAR 18-947/PAR 22-049: "Integrating Biospecimen Science Approaches into Clinical Assay Development"
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
As part of a U01 grants program/network, the Steering Committee provides an opportunity to improve the quality of funded research and potentially amplify the impact of the grants program through collaborative activities. The Steering Committee collaboratively reviews research progress and develops collaborative activities that may include, among other activities, joint research projects, and advocates for the sharing of data and biospecimens within the network.;
|
|
Steering Committee of the Scientific Interest Group in Glycobiology
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIGMS, NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK
|
The Steering Committee of the Scientific Interest Group in Glycobiology (GlycoSIG) is comprised of National Institutes of Health (NIH) intramural scientists and program staff as well researchers from the Food and Drug Administration (FDA) and the National Institute of Standards and Technology (NIST). The committee organizes a seminar series; an annual NIH/FDA Glycosciences Research Day Meeting (averaging 250 people in attendance); and a Mentoring ; Networking Luncheon for graduate students and postdoctoral fellows to meet with staff from federal agencies and learn about NIH extramural programs. The Committee also offers a Special Topics in the Glycosciences Course every other year. In addition, the GlycoSIG maintains an email list serve to distribute information on meetings, jobs, funding opportunities, and seminars. The SIG cross posts with other NIH SIG’s that share interests.
|
|
Stimulating Peripheral Activity to Relieve Conditions (SPARC)
|
Research Initiative
|
FDA
|
OD/DPCPSI/OSC, NCATS, NCCIH, NCI, NEI, NHLBI, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NIMH, NINDS
|
The Stimulating Peripheral Activity to Relieve Conditions (SPARC) program seeks to accelerate development of therapeutic devices that modulate electrical activity in nerves to improve organ function. SPARC has a memorandum of understanding with Food and Drug Administration (FDA) that facilitates coordination and collaboration around common interests and goals in developing neurostimulatory devices for interrogating and elucidating peripheral autonomic and sensory control of organ function to catalyze development of more effective and minimally invasive neuromodulation therapies. SPARC is also collaborating with the FDA through an interagency agreement to support development of technologies in the CDRH/OSEL laboratories for imaging of peripheral nerves to increase understanding of nerve structure, function and neuromodulation safety. SPARC is leveraging an existing NIH interagency agreement (IAA) with the National Aeronautics and Space Administration (NASA) to develop a SPARC Challenge competition (Neuromod Prize) seeking groundbreaking uses of peripheral nerve stimulation that bridge the gap between early-stage research and clinical solutions.
|